Top

European Journal of Medical Research

Published in:

01-12-2010 | Research

GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma

Authors: UH Frey, A Fritz, S Rotterdam, KW Schmid, A Potthoff, P Altmeyer, W Siffert, NH Brockmeyer

Published in: European Journal of Medical Research | Issue 10/2010

Abstract

Background

Once metastasized, despite a variety of therapeutic options, the prognosis of patients with malignant melanoma (MM) is still poor. Therefore, the search for reliable markers to identify patients with high risk of disease progression is of high clinical importance. We have recently shown that TT genotypes of the single-nucleotide polymorphism (SNP) T393C in the gene GNAS1 are significantly associated with better outcome in a variety of carcinomas.

Patients

In the present study we assessed whether the T393C SNP is also related to the clinical course in MM. 328 patients with MM were retrospectively genotyped and genotypes were correlated with clinical outcome.

Results

While the allele frequency in the MM group (fC 0.52) did not significantly differ from that of healthy blood donors, the T393C SNP was associated with tumor progression of MM. Carriers of the C-allele showed a significantly more severe tumor progression as estimated from the time period to develop metastasis (HR 2.2, 95% CI 1.1-3.2, p = 0.017). Proportions of 5-year metastasis-free intervals were 87.1% for TT genotypes and 66.0% for C-allele carriers. Moreover, multivariable Cox regression analysis including tumor stage and melanoma subtype proved the T393C polymorphism to be an independent factor for metastasis (p = 0.012).

Conclusions

In summary, the GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression also in patients with MM; genotyping of this SNP may contribute to better define patients who could benefit from an early individualized therapy.

Rebmann V, Ugurel S, Tilgen W, et al.: Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 2002, 100: 580–5. 10.1002/ijc.10524PubMedCrossRef

Bosserhoff AK, Kaufmann M, Kaluza B, et al.: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997, 57: 3149–53.PubMed

Ugurel S, Rappl G, Tilgen W, et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001, 19: 577–83.PubMed

Ugurel S, Rappl G, Tilgen W, et al.: Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 2001, 7: 1282–6.PubMed

Hauschild A, Engel G, Brenner W, et al.: Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999, 140: 1065–71. 10.1046/j.1365-2133.1999.02905.xPubMedCrossRef

Hauschild A, Engel G, Brenner W, et al.: S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999, 56: 338–44. 10.1159/000011989PubMedCrossRef

Guo HB, Stoffel-Wagner B, Bierwirth T, et al.: Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995, 31A: 924–8.PubMedCrossRef

Henze G, Dummer R, Joller-Jemelka HI, et al.: Serum S100--a marker for disease monitoring in metastatic melanoma. Dermatology 1997, 194: 208–12. 10.1159/000246103PubMedCrossRef

Streit S, Mestel DS, Schmidt M, et al.: FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006, 94: 1879–86. 10.1038/sj.bjc.6603181PubMedCentralPubMedCrossRef

10.

Tsao H, Zhang X, Fowlkes K, et al.: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60: 1800–4.PubMed

11.

Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949–54. 10.1038/nature00766PubMedCrossRef

12.

Okamoto I, Roka F, Krogler J, et al.: The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol 2006, 126: 2242–6. 10.1038/sj.jid.5700377PubMedCrossRef

13.

Frey UH, Eisenhardt A, Lummen G, et al.: The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 2005, 14: 871–7. 10.1158/1055-9965.EPI-04-0720PubMedCrossRef

14.

Frey UH, Alakus H, Wohlschlaeger J, et al.: GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005, 11: 5071–7. 10.1158/1078-0432.CCR-05-0472PubMedCrossRef

15.

Frey UH, Nuckel H, Sellmann L, et al.: The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 2006, 12: 5686–92. 10.1158/1078-0432.CCR-06-0288PubMedCrossRef

16.

Frey UH, Lummen G, Jager T, et al.: The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006, 12: 759–63. 10.1158/1078-0432.CCR-05-1722PubMedCrossRef

17.

Daaka Y, Luttrell LM, Lefkowitz RJ: Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390: 88–91. 10.1038/36362PubMedCrossRef

18.

Krumins AM, Barber R: Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997, 54: 61–72. 10.1016/S0006-2952(97)00147-0PubMedCrossRef

19.

Yang X, Lee FY, Wand GS: Increased expression of Gs(alpha) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 1997, 11: 1053–61. 10.1210/me.11.8.1053PubMed

20.

Yang W, White B, Spicer EK, et al.: Complex haplotype structure of the human GNAS gene identifies a recombination hotspot centred on a single nucleotide polymorphism widely used in association studies. Pharmacogenetics 2004, 14: 741–7. 10.1097/00008571-200411000-00005PubMedCrossRef

21.

Siffert W, Forster P, Jockel KH, et al.: Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999, 10: 1921–30.PubMed

22.

Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19: 3635–48.PubMed

23.

Pho L, Grossman D, Leachman SA: Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 2006, 18: 173–9. 10.1097/01.cco.0000208791.22442.09PubMedCrossRef

24.

Nikolova PN, Pawelec GP, Mihailova SM, et al.: Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 2007, 56: 371–9.PubMedCrossRef

25.

Martinez-Escribano JA, Moya-Quiles MR, Muro M, et al.: Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 2002, 12: 465–9. 10.1097/00008390-200209000-00008PubMedCrossRef

26.

Buettner PG, Leiter U, Eigentler TK, et al.: Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer 2005, 103: 616–24. 10.1002/cncr.20816PubMedCrossRef

27.

Duan J, Wainwright MS, Comeron JM, et al.: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003, 12: 205–16. 10.1093/hmg/ddg055PubMedCrossRef

28.

Capon F, Allen MH, Ameen M, et al.: A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 2004, 13: 2361–8. 10.1093/hmg/ddh273PubMedCrossRef

29.

Tierney MJ, Medcalf RL: Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem 2001, 276: 13675–84.PubMed

30.

Dumaz N, Light Y, Marais R: Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol Cell Biol 2002, 22: 3717–28. 10.1128/MCB.22.11.3717-3728.2002PubMedCentralPubMedCrossRef

31.

Kadekaro AL, Kanto H, Kavanagh R, et al.: Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann N Y Acad Sci 2003, 994: 359–65. 10.1111/j.1749-6632.2003.tb03200.xPubMedCrossRef

32.

Hunt G, Todd C, Cresswell JE, et al.: Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci 1994,107(Pt 1):205–11.PubMed

33.

Dumaz N, Hayward R, Martin J, et al.: In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006, 66: 9483–91. 10.1158/0008-5472.CAN-05-4227PubMedCrossRef

34.

Karasarides M, Chiloeches A, Hayward R, et al.: B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23: 6292–8. 10.1038/sj.onc.1207785PubMedCrossRef

35.

Hingorani SR, Jacobetz MA, Robertson GP, et al.: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63: 5198–202.PubMed

36.

Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949–54. 10.1038/nature00766PubMedCrossRef

Title: GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma
Authors: UH Frey
A Fritz
S Rotterdam
KW Schmid
A Potthoff
P Altmeyer
W Siffert
NH Brockmeyer
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 10/2010
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-15-10-422

Keynote webinar | Spotlight on medication adherence

Springer Medicine

GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma

Abstract

Background

Patients

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2010

Detection of ubiquityl-calmodulin conjugates with a novel high-molecular weight ubiquitylprotein-isopeptidase in rabbit tissues

Reduced expression of Bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance

Immunolocalization of notch signaling protein molecules in a maxillary chondrosarcoma and its recurrent tumor

Pulse wave velocity predicts mortality in renal transplant patients

Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment